Search Results for keywords:"exclusive patent license"

The Department of the Air Force announces its plan to grant an exclusive patent license to Targeted Endo, LLC, a small business located in Golden, Colorado. This license relates to devices and methods for guided endodontic micro-surgery using trephine burs, as detailed in U.S. Application Publication No. 2019/0328486. Interested parties have 15 calendar days from the notice's publication date to submit written objections, if granting the license would contradict the Bayh-Dole Act. Competing applications for patent license agreements can also be submitted during the objection period.

The Department of the Army has announced its intention to grant an exclusive patent license to Dayton Photonics Systems LLC, a business located in Dayton, Ohio. This license covers technologies for free-space optical and laser communications and is related to a specific patent on an optical fiber positioner. Individuals or companies have 15 days from the notice's publication to submit objections or competing applications. Objections must demonstrate that the license grant doesn't meet specific legal requirements.

NASA has announced its intention to grant a patent license to Volt AI, LLC, allowing them to use certain inventions related to wireless sensing systems and other technologies. These inventions are covered by a range of U.S. patents, and NASA will grant either an exclusive, co-exclusive, or partially exclusive license. The public has until March 24, 2025, to submit any written objections or competing applications to prevent the license from being granted. The decision to grant the license is still pending, and NASA retains the right to deny it even if no objections are raised.

The National Institute of Allergy and Infectious Diseases is considering granting an exclusive patent license to Cambridge Enterprise Limited, part of the University of Cambridge, to develop and market certain inventions. These inventions involve conductive polymer coated electrodes used for single-cell electroporation in clinical settings. This license would help consolidate patent rights and speed up the commercial development of the invention, which is in line with promoting innovation according to U.S. law. Public comments or applications for this license must be submitted by May 2, 2025, and will be considered by the institute.

The Department of the Air Force intends to grant an exclusive patent license to the Trustees of Tufts College for a new technology involving optical-based microneedle sensors. These sensors can detect substances in body fluid in a minimally invasive way and offer advantages over other types of sensors, such as longer shelf life and less sensitivity to biofouling. People have 15 days from the publication date to object. If anyone provides a timely and valid objection or submits a competing application, it may be considered as an alternative to granting the license.

The Department of the Air Force, part of the Department of Defense, plans to grant a joint ownership agreement with an exclusive patent license to the University of Alabama in Huntsville. This agreement involves a technology for analyzing digital images to identify a resolution limit with acceptable error margins. The Air Force invites written objections to this grant, which must be submitted within 15 days from the notice's publication. Objections must show that the granting of the license violates the Bayh-Dole Act or its regulations.

The Department of the Air Force has announced its intent to grant an exclusive patent license to Kennon Products, Inc. from Wyoming. This patent relates to a cover for aircraft using collapsible material with programmable magnets. These magnets help the cover stay in place during strong winds without harming the aircraft. The Department will consider objections within 15 days of this notice's publication and will also review any competing patent license applications submitted during this period.

The National Cancer Institute is considering granting an exclusive patent license to Senti Bio for developing and commercializing certain therapies that target CD33-expressing cancers. These therapies involve using specially engineered immune cells, like T cells and NK cells, to recognize and attack cancer cells marked by the CD33 protein, commonly found in acute myeloid leukemia. People interested in this license must submit their comments or applications by January 29, 2021. The patent rights involved have been assigned to the U.S. government, and the license could apply worldwide.